USE OF WEIZMANNIA COAGULANS SG101 IN THE PREPARATION OF AN ANTI-AGING COMPOSITION

Abstract

USE OF WEIZMANNIA COAGULANS SG101 IN THE PREPARATION OF AN ANTI-AGING COMPOSITION The present invention relates to the use of Weizmannia coagulans SG101 in the preparation of an anti-aging composition, whereby the effects of delaying the onsets of reduced learning ability, reduced memory, hair loss or the like can be effectively observed by administering to an individual an effective amount of Weizmannia coagulans SG101 or a composition containing an effective amount of Weizmannia coagulans SG101.

Description

Title of the invention: USE OF WEIZMANNIA COAGULANS SG101 IN THE PREPARATION OF AN ANTI-AGING COMPOSITION Technical field

[0001] The present invention relates to a second use of probiotics, and in particular to a use of Weizmannia coagulans SG101 for the preparation of an anti-aging composition. PRIOR ART

[0002] According to United Nations statistics, the world's elderly population over 65 will exceed 2 billion in 2050, and all countries will then face health and social problems arising from the aging of society. Therefore, the importance of anti-aging issues is gradually increasing, especially how to delay the aging phenomenon, including how to maintain memory and learning ability, as well as external appearance, or the like.

[0003] The aging of the world's population is leading to a sharp increase in the demand for anti-aging products. According to statistics, the market size of anti-aging products is expected to reach US$93.1 billion in 2027, of which nutritional food and health care products account for the largest proportion, followed by the treatment and prevention of aging-related diseases. Currently, all biotechnology and medical industries are investing in the development of anti-aging products and technologies. Therefore, the question of how to produce effective and safe anti-aging products has become an important topic for every manufacturer. Summary of the invention

[0004] A main objective of the present invention is to provide a use of Weizmannia coagulans SG101 in the preparation of an anti-aging composition, wherein the Weizmannia coagulans SG 101 disclosed by the present invention is administered to an individual to delay aging or provide assistance to the individual, in order to achieve the effects of strengthening the posture and health of the individual.

[0005] Therefore, in order to achieve the above-mentioned objective, the present invention discloses a second use of Weizmannia coagulans SG101 against aging or other related diseases, Weizmannia coagulans SG101 having been deposited in the German Collection of Microorganisms and Cell Cultures GmbH (Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, DSMZ) under the order number DSM34661 on 06 / 08 / 2023. Therefore, the aging phenomena of an individual can be effectively delayed by administering to the individual an effective amount of the Weizmannia coagulans SGI01 disclosed by the present invention or a composition containing an effective amount of the Weizmannia coagulans SG 101, thereby, for example, delaying memory decline, shortening learning time, preventing hair loss, maintaining posture or the like.

[0006] One embodiment of the present invention discloses Weizmannia coagulans SG101 as defined above for use in the preparation of an anti-aging composition, wherein the anti-aging composition may be a food product, a nutritional supplement, a pharmaceutical product or a health care product.

[0007] For example, when the anti-aging composition is a nutritional supplement, it contains Weizmannia coagulans SG101 and nutritionally acceptable components, which include other nutrients, sweeteners, flavoring agents, excipients, or the like; and when the anti-aging composition is a health care product, it contains Weizmannia coagulans SG101 and cosmetically acceptable components, which include antibiotics, excipients, thickeners, emulsifiers, and other ingredients having health care activities.

[0008] Advantageously, the anti-aging composition is intended to be used to improve learning abilities.

[0009] Advantageously, the anti-aging composition is intended to be used to improve memory.

[0010] Advantageously, the anti-aging composition is intended to be used to delay apparent aging. Brief description of the drawings

[0011] [Fig. 1 A] shows the appearance of a mouse in a control group at Week 11 of a test ; and

[0012] [Fig.lB] shows the appearance of a mouse in a SG101 strain group at Week 11 of a test.

[0013] DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0014] The present invention discloses a use of Weizmannia coagulans SG101 in the preparation of an anti-aging composition, whereby the onset of aging can be effectively delayed by administering to an individual an effective amount of Weizmannia coagulans SG101 or a composition containing an effective amount of Weizmannia coagulans SG101.

[0015] The Weizmannia coagulans SG101 disclosed by the present invention has been deposited in the German Collection of Microorganisms and Cell Cultures GmbH (Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, DSMZ) under accession number DSM34661 on 08 / 06 / 2023.

[0016] In one embodiment of the present invention, the anti-aging composition is a lozenge, a capsule, a powder, a liquid, or any other edible dosage form. For example, when the anti-aging composition is prepared in the form of a lozenge, the anti-aging composition has a multi-layered structure and comprises at least a core and a coating layer. Incorporated into the core is the Weizmannia coagulans SG101 disclosed by the present invention, and the coating layer is coated on the surface of the core to protect the core and the Weizmannia coagulans SG101 contained therein from deterioration caused by environmental factors.

[0017] The "aging" or "senility" mentioned in the present invention refers to the decline in appearance, memory, learning ability and mobility caused by increasing age. For example, aging of appearance includes hair loss, wrinkles, decreased skin luster or the like; and aging of memory and / or learning ability includes shortening of memorization time, lengthening of learning time, memory loss or the like.

[0018] In the following, several experimental examples are presented in combination with the description of drawings in order to illustrate the effects which can be obtained by the technical characteristics disclosed by the present invention.

[0019] The dose of Weizmannia coagulans SG101 as disclosed in the following examples is determined according to the animals used in these examples, and the technical characteristics of the present invention are not limited thereto. The person skilled in the art, to which the present invention belongs, having common general knowledge, can adjust the dose according to the species receiving the administration on the basis of his inherent knowledge. Example 1: Probiotic Culture

[0020] The Weizmannia coagulans SG101 disclosed by the present invention was obtained by preparation methods such as rearing and culturing for 15 hours in carbon and nitrogen-based culture media, centrifugal separation, freezing, drying and grinding. Example 2: Animal Testing

[0021] 3-month-old SAMP8 mice were randomly divided into 2 groups, including:

[0022] a control group: tube perfusion with water (ddH2O) twice; and

[0023] a group of strain SG101: daily tube perfusion with the Weizmannia coagulans SG101 disclosed by the present invention at a dose of 1.0 x 109 CFU / mouse / day.

[0024] The test was carried out for a total of 13 weeks. During the test, the weight, food consumption and water consumption of the mice were recorded, as shown in Table 1 below; and the mice in each group were analyzed successively for different functional indices.

[0025] According to the results in Table 1 below, no significant difference was observed between the control group and the SG101 strain group, indicating that the Weizmannia coagulans SG 101 disclosed by the present invention did not affect the eating habits of individuals.

[0026] Table 1: Evolution of weight, food consumption and water consumption of mice in each group after 13 weeks of testing Group Weight(g) Food Consumption (g / day) Water Consumption (ml / day) Start End Increase Control Group 28.72+0.41 30.92+0.88 2.20+0.62 5.31+0.04 7.19+0.17 SG101 Strain Group 28.09+0.49 31.03+0.83 2.94+0.72 5.19+0.05 7.47+0.34

[0027] At the end of the test, the mice in each group were sacrificed and their brain, heart, liver, spleen, lungs and kidneys were extracted for visual observation. No abnormalities were found in the SG101 strain group. The organs of the mice in each group were weighed, the results being shown in Table 2 below. The results in Table 2 below showed no significant difference in the relative organ weights between the mice in these groups.

[0028] [Tables2] Group Relative organ weight (g / 100 g body weight) Brain Heart Liver Spleen Lung Kidney Control group 1.46 + 0.68 + 5.38 + 0.28 + 0.76 + 1.68 + 0.05 0.03 0.14 0.02 0.03 0.04 Strain group 1.47 + 0.66 + 4.91 + 0.30 + 0.78 + 1.69 + SG101 0.02 0.02 0.15 0.02 0.03 0.03 Example 3: Single Passive Avoidance Test

[0029] The single passive avoidance test was performed on the mice in each group of Example 2 during Week 12. An aluminum box of 35 (W) x 17 (D) x 20 (H) cm3 was used, in which metal defibrillators were arranged in parallel in a lower layer. The aluminum box was divided into two spaces by an aluminum foil in the middle and was provided with an automatic small door. The left space was covered with a black cover plate to form a dark chamber, and the right space was a light chamber. During the test, the mouse was first placed in the light chamber and could move freely 10 seconds after the small door was automatically opened. After the mouse entered the dark chamber, the small door was closed.After 5 seconds, a 0.5 microampere electric shock was delivered for 0.5 seconds, and three electric shocks were delivered continuously every 5 seconds. If the mouse did not enter the dark chamber within 180 seconds, the test ended automatically, and the residence time in the light chamber was recorded. On Day 1, learning training was conducted by administering electric shocks. After the learning training was completed, the power supply was turned off without giving an electric shock. The test was carried out successively after 24 h, 48 h, and 72 h, and the residence time in the light chamber was recorded each time. The results on the residence time of the mice in each group in the light chamber were recorded as shown in Table 3 below.

[0030] According to the results in Table 3, after 24h, 48h and 72h of learning, the residence time of the mice of the SG101 strain group in the clear room was obviously longer than that of the mice of the control group. These results showed that it is possible to effectively improve the learning memory of individuals by administering to them the Weizmannia coagulans SG101 disclosed by the present invention, which helps delay the decline in memory and learning ability caused by aging.

[0031] Table 3: Residence time of mice in each group after a test unique passive avoidance Group Residence time Start of test 24 h 48 h 72 h Control group 37.75+2.49 48.25+1.6 43.63+2.31 42.25+1.87 SG101 strain group 37.88+2.73 69.00+3.14 62.00+2.24 52.13+3.33 Example 4: Active Avoidance Test

[0032] The active avoidance test was performed on the mice in each group of Example 2 during Week 13. The foil described in Example 3 was used, except that the left and right spaces were both clear chambers. During the test, the control time, sound and light, and electric shock were programmed by a computer. During the test, the mouse was first set aside and acclimated for 10 seconds (intertrial interval), immediately after which the computer delivered sound and light stimuli (conditioned stimuli, CS) for 10 seconds. If the mouse still remained on the same side without responding to the sound and light stimuli, the computer immediately administered an electric shock (unconditioned stimulus, UCS) of 0.3 microamperes for 5 seconds. If the mouse moved to the other side in response to the sound and light stimuli, no electric shock was administered.During the test, if the mouse remained in the same place, the computer administered the electric shock again; and if the mouse responded by moving, the computer did not administer the electric shock. Each time, the mouse was tested 5 times with sound and light stimuli and electric shocks. After an interval of 15 to 20 minutes, the same test of sound and light stimuli and electric shocks was carried out again, 4 times a day for 4 days. The results of the active avoidance test for the mice in each group are shown in Table 4 below.

[0033] From the results in Table 4, except for Day 1, the mice in the SG 101 strain group showed a significantly higher escape frequency than those in the control group, indicating a better learning ability of the mice in the SG101 strain group. It can therefore be seen that the effect of increasing the learning and memory abilities of an individual can be achieved by administering the Weizmannia coagulans SG101 disclosed in the present invention.

[0034] Table 4: Results of the active avoidance test for mice in each group Group Test day Day 1 Day 2 Day 3 Day 4 Control group 6.88+0.93 10.13+0.61 12.00+0.87 14.38+0.71 SG101 strain group 6.88+0.61 13.13+0.69 15.88+0.81 17.25+0.25

[0035] Example 5: Evaluation of aging indices

[0036] Referring to Figures 1A and 1B, the mice in each group of Example 2 were evaluated for aging indices at Week 11. The evaluated items of the aging indices include behavior and change in appearance, with behavior including reactivity (i.e., exploration of space by the mice within 30 seconds on the test plate) and passivity (i.e., passivity of the mouse when the neck fur is gently pinched); and change in appearance including hair gloss, hair roughness, hair loss, skin ulcer, periocular lesion or eyelid edema, lordosis, kyphosis of the spine inspected and touched. Five levels were established for each element, namely 0, 1, 2, 3, and 4, and the mice were scored according to the definition of each level. The higher the score, the more severe the aging.The results of the aging indices evaluated are presented in Table 5 below.

[0037] According to the results in Table 5, the mice in the SG101 strain group did not exhibit hair loss or skin ulcers and had better posture and appearance than the control group. Overall, the total score of aging indices in the SG101 strain group was lower than that in the control group, and there was no significant difference between the two groups (p<0.05). These results show that the Weizmannia coagulans SGI01 disclosed by the present invention and the composition containing the Weizmannia coagulans SG101 of the present invention can effectively delay aging and maintain the appearance of an individual.

[0038] Table 5: Aging indices of mice in each group Control group SG101 strain group Behavior Reactivity 0.25+0.15 0.25+0.15 Passivity 0.38+0.16 0.38+0.16 Skin Shine 1.25+0.15 0.13+0.11 Roughness 1.00+0.00 0.25+0.15 Hair loss 1.63+0.16 0.00+0.00 Skin ulcer 0.13+0.11 0.00+0.00 Eyes Periophthalmic lesion or eyelid edema 0.13+0.11 0.38+0.16 Spine Lordosis kyphosis of the spine 1.50+0.17 1.13+0.11 Total score 6.25+0.55 2.88+0.36 Example 6: Biochemical analysis of serum

[0039] At the end of the test, Week 13, blood was collected from the mice in each group of Example 2 for biochemical analysis, the results of which are shown in Table 6 below.

[0040] The results in Table 6 show that mice in the SG101 strain group had an obvious decrease in blood glucose (p<0.05) and an obvious increase in high-density lipoprotein cholesterol value (p<0.05), compared with the control group.

[0041] Table 6: Biochemical values of the blood of mice in each group Group Control group SG101 strain group Glucose (mg / dl) 91.31+1.90 74.46+2.50 Total protein (g / dl) 5.43+0.05 5.45+0.07 Albumin (g / dl) 3.27+0.07 3.29+0.05 Triglycerides (mg / dl) 109.75+2.17 96.25+3.11 Total cholesterol (mg / dl) 125.75+3.02 117.50+2.45 High-density lipoprotein cholesterol (HDL-C) (mg / dl) 52.13+1.77 67.29+2.24 High-density lipoprotein cholesterol 5.98+0.41 7.14+0.31 Low Density Protein (LDL-C) (mg / dl) Aspartate Transaminase (AST) (U / L) 84.38+2.58 80.06+2.09 Alanine Transaminase (ALT)(U / L) 54.25+2.53 50.13+1.84 Urea Nitrogen (B UN) (mg / dl) 27.00+2.19 23.50+0.68 Creatinine (CREA) (mg / dl) 0.25+0.02 0.20+0.01 Blood Uric Acid (UA) (mg / dl) 4.14+0.11 4.04+0.28

Claims

Claims

1. Use of Weizmannia coagulans SG101 in the preparation of an anti-aging composition, Weizmannia coagulans SG101 having been deposited in the German Collection of Microorganisms and Cell Cultures GmbH (Deutsche Sammlung von Mikroorganismen und Zell-kulturen GmbH, DSMZ) under the accession number DSM34661 on 08 / 06 / 2023.

2. Use of Weizmannia coagulans SG101 in the preparation of an anti-aging composition according to claim 1, characterized in that the anti-aging composition is a food product.

3. Use of Weizmannia coagulans SG101 in the preparation of an anti-aging composition according to claim 1, characterized in that the anti-aging composition is a nutritional supplement.

4. Use of Weizmannia coagulans SG101 in the preparation of an anti-aging composition according to claim 1, characterized in that the anti-aging composition is a health care product.

5. Use of Weizmannia coagulans SG101 in the preparation of an anti-aging composition according to claim 1, characterized in that the anti-aging composition is intended to be used to improve learning abilities.

6. Use of Weizmannia coagulans SG101 in the preparation of an anti-aging composition according to claim 1, characterized in that the anti-aging composition is intended to be used to improve memory.

7. Use of Weizmannia coagulans SG101 in the preparation of an anti-aging composition according to claim 1, characterized in that the anti-aging composition is intended to be used to delay apparent aging.

Images